Lumosa Therapeutics CoROCO:6535 -1.41%72 Quick Ratio is 6.62 as of Dec. 2025, which is 3% below its 10-year median of 6.83. GuruFocus rates ROCO:6535 with a GF Score™ of 72/100 and a GF Value™ of NT$130.86 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 1,412 Biotechnology companies, Lumosa Therapeutics Co ranks better than 67.78% on this metric.
Lumosa Therapeutics Co has a quick ratio of 6.62. It generally indicates good short-term financial strength.
The historical rank and industry rank for Lumosa Therapeutics Co's Quick Ratio or its related term are showing as below:
ROCO:6535'
s Quick Ratio Range Over the Past 10 Years
Min: 3.43 Med: 6.83 Max: 18.76
Current: 6.62
During the past 13 years, Lumosa Therapeutics Co's highest Quick Ratio was 18.76. The lowest was 3.43. And the median was 6.83.
ROCO:6535's Quick Ratio is ranked better than 67.78% of 1412
companies
in the Biotechnology industry
Industry Median: 3.6
vs ROCO:6535: 6.62
Lumosa Therapeutics Co (ROCO:6535) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Lumosa Therapeutics Co Quick Ratio Related Terms
Lumosa Therapeutics Co Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6535 vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, Lumosa Therapeutics Co's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lumosa Therapeutics Co Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lumosa Therapeutics Co's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Lumosa Therapeutics Co's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Lumosa Therapeutics Co's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lumosa Therapeutics Co (ROCO:6535) has a Quick Ratio of 6.62 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Lumosa Therapeutics Co and its competitors. This is near median its historical median of 6.83. Over the past decade, Lumosa Therapeutics Co's Quick Ratio has ranged from 3.43 to 18.76. According to the industry distribution chart, Lumosa Therapeutics Co ranks #455 out of 1412 companies in the Biotechnology industry, placing it in the top 32.2%.
Is Lumosa Therapeutics Co's Quick Ratio too high?
Lumosa Therapeutics Co's current Quick Ratio of 6.62 is near median its 10-year median of 6.83. Over the past 10 years, this metric has ranged from a low of 3.43 to a high of 18.76. The Biotechnology industry median Quick Ratio is 3.60. Lumosa Therapeutics Co's value of 6.62 is 83.9% above this industry median. Based on the distribution chart, Lumosa Therapeutics Co ranks #455 out of 1412 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Lumosa Therapeutics Co has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lumosa Therapeutics Co's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lumosa Therapeutics Co ranks #455 out of 1412 companies for Quick Ratio. This puts Lumosa Therapeutics Co in the upper half of its industry. The industry median Quick Ratio is 3.60. Lumosa Therapeutics Co's value of 6.62 is 83.9% above this benchmark. Historically, Lumosa Therapeutics Co's own Quick Ratio has ranged from 3.43 to 18.76 over the past decade. While the company's 10-year median is 6.83 vs. the industry median of 3.60, Lumosa Therapeutics Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lumosa Therapeutics Co's current Quick Ratio of 6.62 is 83.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Lumosa Therapeutics Co and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lumosa Therapeutics Co's current Quick Ratio is 6.62, which is near median its own 10-year median of 6.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumosa Therapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, Lumosa Therapeutics Co (ROCO:6535) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$130.86, compared to a current price of NT$98.10 — trading 25% below its estimated fair value. The current Quick Ratio is 6.62, which is near median its 10-year median of 6.83 and 83.9% above the Biotechnology industry median of 3.60. Lumosa Therapeutics Co's overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Lumosa Therapeutics Co (ROCO:6535), the current Quick Ratio is 6.62 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lumosa Therapeutics Co (ROCO:6535) Overvalued in 2026?
Based on GuruFocus' analysis, Lumosa Therapeutics Co stock appears to be undervalued.
The current stock price of NT$98.10 is trading 25% below its estimated GF Value™ of NT$130.86.
GuruFocus considers Lumosa Therapeutics Co to be Modestly Undervalued.
Key valuation signals for ROCO:6535:
Quick Ratio: 6.62 (near median its 10-year median of 6.83)
GF Value™: NT$130.86 vs. price of NT$98.10 (25% below fair value)
Industry Position: 83.9% above the Biotechnology median (#455 of 1412)
No single metric tells the full story. See the ROCO:6535 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lumosa Therapeutics Co Ltd develops new drugs. The company is engaged in the development of drugs for unmet medical needs in the fields of oncology and Neuroscience. Geographically, it derives a majority of its revenue from Taiwan and also has a presence in Asia, and America. The product pipeline of the company is Neuroscience, which includes LT 1001 for Postoperative Pain, LT 3001 for Acute Ischemic Stroke, LT 5001 for Uremic Pruritus, LT 6001 for Neurological disorder, and Oncology, including LT 2003 for Solid Tumor. It generates revenue from sales of goods.
72GF Score
Get the complete analysis for ROCO:6535
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6535 has been successfully added to your 
